An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. Dailey KM, Small JM, Pullan JE, Winfree S, et al. PLoS One 2023;18:e0289183.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dailey KM, Small JM, Pullan JE, Winfree S, et al. An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. PLoS One 2023;18:e0289183.
PMID: 37963142